Final guidance issued on Herceptin after appeal rejectedBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7565.409 (Published 24 August 2006) Cite this as: BMJ 2006;333:409
- Caroline White
The National Institute for Health and Clinical Excellence (NICE) has issued its final guidance to English and Welsh health service trusts for the use of trastuzumab (Herceptin) for the treatment of early stage breast cancer in women with HER2 positive disease and free of heart disease.
The final guidance is based on an initial draft published earlier this year (BMJ 2006; 332: 1409). It recommends that:
Herceptin be provided at three weekly intervals for a year or until disease recurrence—whichever is sooner—after surgery, chemotherapy, and radiotherapy, if …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial